facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2017
vol. 104
 
Share:
Share:
abstract:
Review paper

Localized scleroderma – current treatment options

Katarzyna Wolska-Gawron
,
Małgorzata Michalska-Jakubus
,
Dorota Krasowska

Dermatol Rev/Przegl Dermatol 2017, 104, 606-618
Online publish date: 2017/12/05
View full text Get citation
 
PlumX metrics:
Localized scleroderma (morphea) is a connective tissue disease that affects the skin, subcutaneous tissue and underlying tissues including the fasciae, muscles and bones. The treatment of localized scleroderma depends on the clinical form of the disease, its severity/activity, extent of skin lesions and patient’s age. Patients with limited skin involvement caused by morphea require topical therapy with glucocorticoids, calcineurin inhibitors, calcipotriol or UVA/PUVA phototherapy. More severe variants of localized scleroderma with extensive tissue involvement require immediate systemic therapy with glucocorticoids and/or methotrexate, or mycophenolate mofetil. According to recent reports, attempts have also been taken, with variable clinical outcomes, to treat localized scleroderma topically with pirfenidone and imiquimod, systemically with tacrolimus and cyclosporine; and with fractional CO2 laser, photodynamic therapy and autologous fat transfer. The article presents current therapeutic methods of localized scleroderma.
keywords:

glucocorticosteroids, methotrexate, phototherapy, therapy, tacrolimus, calcipotriol



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.